PHE Weekly National Influenza Report

Summary of UK surveillance of influenza and other seasonal respiratory illnesses
12 December 2019 – Week 50 report (up to week 49 data)

This report is published weekly on the PHE website. For further information on the surveillance schemes mentioned in this report, please see the PHE website and the related links at the end of this document.

Summary – Week 49 (ending 08 December 2019)

- During week 49, influenza activity has continued to increase for several indicators.
- The impact of flu on healthcare services is moderate intensity levels for hospitalisations and above baseline for ICU/HDU influenza admissions. The Department of Health & Social Care has issued an alert on the prescription of antiviral medicines by GPs.
- Respiratory Syncytial Virus (RSV) continues to circulate in the <5 year olds in England.

Community

- 165 new acute respiratory outbreaks have been reported in the past 7 days. 49 outbreaks were reported from care homes where 22 tested positive for influenza A. 17 outbreaks were reported from hospitals where 13 tested positive for influenza A. 94 outbreaks were reported from schools where 26 tested positive for influenza A(not subtyped). The remaining 5 outbreaks were from the Other settings category, where two tested positive for influenza A(not subtyped).

Primary Care

<table>
<thead>
<tr>
<th>GP ILI Consultations England</th>
</tr>
</thead>
<tbody>
<tr>
<td>The rate of influenza-like illness (ILI) was Above baseline threshold levels for the first time this season. The overall weekly ILI GP consultation rate was 13.1 per 100,000 registered population in participating GP practices for England, an increase from 10.6 per 100,000 in the previous week.</td>
</tr>
<tr>
<td>In the devolved administrations, ILI rates were below baseline threshold levels for Scotland and Wales, however were at moderate levels in Northern Ireland.</td>
</tr>
</tbody>
</table>

Secondary Care

<table>
<thead>
<tr>
<th>Hospitalisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospitalisation rate observed for laboratory confirmed influenza continues to be at moderate intensity levels with a rate of 5.06 per 100,000 trust catchment population for England (21 NHS Trusts) compared to 4.01 per 100,000 in the previous week.</td>
</tr>
<tr>
<td>ICU/HDU admission rate observed for laboratory confirmed influenza was above baseline levels, with a rate of 0.22 per 100,000 trust catchment population for England (134/143 NHS Trusts) compared to 0.15 per 100,000 the previous week.</td>
</tr>
<tr>
<td>There were no laboratory confirmed influenza admission reported from the 6 Severe Respiratory Failure centres in the UK.</td>
</tr>
</tbody>
</table>

All-cause mortality

- In week 49 2019, no statistically significant excess all-cause mortality by week of death was seen overall and by age group in England. In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Wales and Northern Ireland for week 49 and for Scotland in week 47 2019.

Microbiological surveillance

<table>
<thead>
<tr>
<th>Secondary Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary care: 66 samples tested positive for influenza (2 influenza A(H1N1)pdm09, 59 influenza A(H3), 4 influenza A(not subtyped) and one co-infection of influenza A(not subtyped) and influenza B), through the UK GP sentinel swabbing schemes in week 49 2019, with an overall influenza positivity of 36.6%.</td>
</tr>
<tr>
<td>Secondary care: There were 546 influenza detections recorded through the DataMart scheme (12 influenza A(H1N1)pdm09, 410 influenza A(H3), 113 influenza A(not subtyped) and 11 influenza B). The overall influenza percent positivity was 17.9% and Above baseline threshold level.</td>
</tr>
<tr>
<td>Virus Characterisation: 154 influenza A(H3N2) viruses have been genetically and/or antigenically characterised since week 40. 111 of 135 genetically characterised belong to the same subtype as the H3N2 component in this season’s vaccine. Six A(H1N1)pdm09 viruses have been antigenically characterised and are similar to the A(H1N1)pdm09 strain in this season’s vaccine.</td>
</tr>
</tbody>
</table>

Vaccination

<table>
<thead>
<tr>
<th>Vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weekly uptake: Up to week 49 2019, in 93.2% of GP practices reporting for the main collection, the provisional proportion of people in England who had received the 2019/20 influenza vaccine in targeted groups was: 37.1% in under 65 years in a clinical risk group, 38.8% in pregnant women and 68.5% in 65+ year olds. In 92.8% of GP practices reporting for the childhood collection, the provisional proportion vaccinated was: 28.9% in 2 year olds and 28.1% in 3 year olds.</td>
</tr>
<tr>
<td>Provisional data from the first monthly collection of influenza vaccine uptake by frontline healthcare workers show 43.6% were vaccinated by 31 October 2019, compared to 46.3% vaccinated in the previous season by 31 October 2018.</td>
</tr>
<tr>
<td>Provisional data from the first monthly collection of influenza vaccine uptake for children of school years reception to year 6 shows 17.9% in school year reception age, 17.6% in school year 1 age, 17.3% in school year 2 age, 16.6% in school year 3 age, 16.4% in school year 4 age, 15.8% in school year 5 and 15.2% in school year 6 were vaccinated on 31 October 2019.</td>
</tr>
</tbody>
</table>

International situation

- In the temperate zone of the northern hemisphere, influenza activity and respiratory illness indicators started to increase in most countries with influenza activity elevated across the countries in Western Asia. In the temperate zones of the southern hemisphere, influenza activity returned to interseasonal levels. Worldwide, seasonal influenza A(H3N2) viruses accounted for the majority of detections.

See the PHE website and the related links at the end of this document for further information.
Community surveillance

165 new acute respiratory outbreaks were reported in the past 7 days, with 63 confirmed with influenza. ILI rates observed through internet based surveillance increased and breached the baseline threshold for the FluDetector system.

- Acute respiratory disease outbreaks
  - 165 new acute respiratory outbreaks have been reported in the past 7 days. 49 outbreaks were reported from care homes where 21 tested positive for influenza A (not subtyped) and one tested positive for influenza A(H3). 17 outbreaks were reported from hospitals where 10 tested positive for influenza A (not subtyped) and 3 for influenza A(H3). 94 outbreaks were reported from schools where 26 tested positive for influenza A (not subtyped). The remaining 5 outbreaks were from the Other settings category where two tested positive for influenza A (not subtyped).
  - Outbreaks should be recorded on HPZone and reported to the local Health Protection Teams and resp cidsc@phe.gov.uk

- Medical Officers of Schools Association (MOSA) & PHE surveillance scheme
  - Boarding schools in England within the MOSA network are recruited each season to report various respiratory related illnesses including influenza like illnesses (ILI). For the 2019/20 season, 17 MOSA schools have agreed to participate in the scheme, including a total of 4,000 boarders.
  - The overall rate (all boarders) for week 49 was 2.5 per 1,000 boarders compared to 3.2 per 1,000 boarders in the previous week. Since week 40, three outbreaks have been reported with a total of 15 ILI cases.
  - If you are a MOSA school and would like to participate in this scheme, please email mosa@phe.gov.uk for more information.

- FluSurvey
  - Internet-based surveillance of influenza-like illness in the general population is undertaken through FluSurvey. A project run by PHE to monitor ILI activity in the community.
  - The overall ILI rate (all age groups) for week 49 was 30.4 per 1,000 (42/1,381 people reported at least 1 ILI), with the highest rate seen in the < 20 year olds (145.2 per 1,000).
  - If you would like to become a participant of the FluSurvey project please do so by visiting the https://flusurvey.net/en/accounts/register/ website for more information.

- FluDetector
  - Internet-based surveillance of influenza-like illness in the general population is also undertaken through FluDetector (https://fludetector.cs.ucl.ac.uk), a model assessing internet-based search queries for ILI.
  - Daily ILI rate estimates are based on uniformly averaged search query frequencies for a week-long period (including the current day and the six days before it).
  - The daily ILI rate estimates for week 49 increased but were below the baseline threshold of 11.7 per 100,000, with an overall weekly rate of 19.2 per 100,000 compared to 15.8 per 100,000 in week 48 (Figure 2).
  - For more information on i-sense and the work carried out on early warning sensing systems for infectious disease visit https://www.i-sense.org.uk/
In week 49, the overall weekly influenza-like illness (ILI) GP consultation rate breached the baseline threshold in England. In the devolved administrations, ILI rates were below their respective baselines for Scotland and Wales but at moderate levels in Northern Ireland.

- GP ILI consultations in the UK

**RCGP (England)**
- The weekly ILI consultation rate through the RCGP surveillance was 13.1 per 100,000 registered population in participating GP practices in week 49 compared to 10.6 per 100,000 in week 48. This is above the baseline threshold (12.7 per 100,000) (Figure 3*). By age group, the highest rates were seen in the 1-4 year olds (21.4 per 100,000) and in the 5-14 year olds (18.0 per 100,000).

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10) in a standardised approach across Europe. For MEM intensity threshold values, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#clinical-surveillance-through-primary-care

**UK**
- In week 49, overall weekly ILI consultation rates were below their respective baseline threshold levels in Scotland and Wales and at moderate levels in Northern Ireland (Table 1).
- By age group, the highest rates were seen in the 15-44 year olds in Scotland (18.2 per 100,000) and in the 5-14 year olds in Northern Ireland (41.1 per 100,000 respectively). Age group rates were not available for Wales.

**Table 1: GP ILI consultations in the UK for all ages with MEM thresholds applied***

<table>
<thead>
<tr>
<th>GP ILI consultation rates (all ages)</th>
<th>Week number</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 41 42 43 44 45 46 47 48 49 50 51 52 1 2 3 4</td>
<td></td>
</tr>
<tr>
<td><strong>England (RCGP)</strong></td>
<td>4.3 4.8 4.4 4.2 5.8 5.2 5.5 6.5 6.2 6.4 5.8 0.0 0.0 0.0 0.0</td>
</tr>
<tr>
<td><strong>Wales</strong></td>
<td>1.7 4.0 4.2 4.2 1.7 4.2 3.7 10.1 10.6 10.6 7.4</td>
</tr>
<tr>
<td><strong>Scotland</strong></td>
<td>5.1 6.2 4.4 4.0 7.9 5.0 7.5 11.6 12.3 14.1</td>
</tr>
<tr>
<td><strong>Northern Ireland</strong></td>
<td>3.9 4.8 4.6 4.6 5.1 6.5 7.2 6.9 14.2 28.2 29.2</td>
</tr>
</tbody>
</table>

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10), in a standardised approach across Europe. For MEM threshold values for each country, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#clinical-surveillance-through-primary-care

**GP In Hours Syndromic Surveillance System (England)**

The weekly ILI consultation rate through the GP In Hours Syndromic Surveillance system is 10.5 per 100,000 in week 49 2019 (Figure 4).

GP In Hours consultations for ILI increased above baseline and are now at low intensity levels for week 49, with the highest levels observed in the North East and North West.

NHS 111 cold/flu calls continued to increase and remain at medium intensity levels with highest activity noted in the 5-14 years age group and in the North of England. Cough calls and difficulty breathing continued to increase, particularly in young children aged under 1 year, in line with seasonal RSV.

GP Out of Hours contacts and Emergency Department (ED) attendances for ILI continued to increase, with activity in the medium intensity levels for GP Out of Hours contacts. ED attendances for bronchiolitis also showed a further increase in young children aged less than 1 year in line with seasonal increases in RSV.

- Figure 4 represents a map of GP ILI consultation rates in week 49 across England by PHE centres, with influenza-like illness surveillance MEM thresholds applied.

ILI thresholds were calculated separately for each of the nine PHE Centres to allow for differences between areas e.g. background ILI rates are historically higher in London than other areas of England and based upon previous influenza seasons from 2012/13 onwards. ILI thresholds should be interpreted with caution and reference made to other GP surveillance systems incorporating more historical data.
In week 49 2019, there were 472 hospitalised confirmed influenza cases (6 influenza A(H1N1)pdm09, 187 influenza A(H3N2) and 265 influenza A(not subtyped) and 14 influenza B) reported through the USISS sentinel hospital network across England (21 Trusts). There were 124 new admissions to ICU/HDU with confirmed influenza (9 influenza A(H1N1)pdm09, 26 influenza A(H3N2), 87 influenza A(not subtyped) and 2 influenza B) reported through the USISS mandatory ICU/HDU surveillance scheme across the UK (134/143 Trusts in England).

- USISS sentinel weekly hospitalised confirmed influenza cases, England (week 49)

In week 49, there were 472 hospitalised laboratory confirmed influenza cases (6 influenza A(H1N1)pdm09, 187 influenza A(H3N2), 265 influenza A(not subtyped) and 14 influenza B) reported from 21 NHS Trusts across England through the USISS sentinel hospital network, with a rate of 5.06 per 100,000 trust catchment population (Figures 5 and 6) compared to 4.01 per 100,000 in week 48. This is at medium intensity levels.

A total of 1,496 hospitalised confirmed influenza admissions (712 influenza A(H3N2), 717 influenza A(not subtyped), 27 influenza A(H1N1)pdm09 and 40 influenza B) have been reported in England since week 40 2019 via the sentinel scheme.

- Number of new admissions and fatal confirmed influenza cases in ICU/HDU (USISS mandatory ICU scheme), UK (week 49)

In week 49, there were 124 new admissions to ICU/HDU with confirmed influenza (9 influenza A(H1N1)pdm09), 26 influenza A(H3N2), 87 influenza A(not subtyped) and 2 influenza B) reported across the UK (134/143 Trusts in England) through the USISS mandatory ICU scheme, with a rate of 0.22 per 100,000 (Figures 7 and 8) compared to 0.15 per 100,000 in week 48. This is above the baseline impact threshold of 0.10 per 100,000. Eight influenza laboratory confirmed deaths were reported to have occurred in ICU/HDU week 49 in the UK.

A total of 346 new admissions (26 influenza A(H1N1)pdm09, 67 influenza A(H3N2), 237 influenza A(not subtyped) and 16 influenza B) and 15 confirmed deaths have been reported in the UK since week 40 2019.

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for ICU/HDU admission rates for the start of influenza activity (based on 7 seasons) in a standardised approach across Europe. For MEM threshold values, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk/disease-severity-and-mortality-data
• USISS Severe Respiratory Failure Centre confirmed influenza admissions, UK (week 49)
  - In week 49, there were no new admissions for laboratory confirmed influenza among the 6 Severe Respiratory Failure (SRF) centres in the UK. Since week 40 2019, a total of 3 confirmed influenza admissions (1 influenza A(H3N2) and 2 influenza A(unknown subtype)) have been reported among the 6 centres in the UK.

**All-cause mortality data**

In week 49 2019, no statistically significant excess all-cause mortality by week of death was observed overall and by age group in England, through the EuroMOMO algorithm. In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Wales and Northern Ireland in week 49 2019 and for Scotland in week 47.

- All-cause death registrations, England and Wales
  - In week 48 2019, an estimated 10,958 all-cause deaths were registered in England and Wales (source: Office for National Statistics). This is an increase compared to the 10,882 estimated death registrations in week 47 2019.

- Excess all-cause mortality by age group, England, Wales, Scotland and Northern Ireland
  - In week 49 2019 in England, no statistically significant excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group and sub-nationally (all ages), after correcting ONS disaggregate data for reporting delay with the standardised EuroMOMO algorithm. This data is provisional due to the time delay in registration; numbers may vary from week to week.

  - In the devolved administrations, no statistically significant excess all-cause mortality for all ages observed in Wales and Northern Ireland in week 49 2019 and for Scotland in week 47 (Table 2).

**Table 2: Excess mortality by UK country, for all ages**

<table>
<thead>
<tr>
<th>Country</th>
<th>Excess detected in week 49 2019?</th>
<th>Weeks with excess in 2019/20</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>×</td>
<td>NA</td>
</tr>
<tr>
<td>Wales</td>
<td>×</td>
<td>42</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>×</td>
<td>NA</td>
</tr>
<tr>
<td>Scotland</td>
<td>×</td>
<td>41, 46</td>
</tr>
</tbody>
</table>

* Excess mortality is calculated as the observed minus the expected number of deaths in weeks above threshold
* NA refers to no excess seen

**Figure 9: Weekly observed and expected number of all-age all-cause deaths, with the dominant circulating influenza A subtype, England, 2015 to week 49 2019**

*Note: Delays in receiving all registered deaths from April 2018, following changes in IT systems at ONS, may result in some delays in the model to adjust for most recent deaths.*

5 of 12
In week 49 2019, 66 samples tested positive for influenza with an overall positivity of 36.6%, through the UK GP sentinel schemes. 546 positive detections were recorded through the DataMart scheme (12 influenza A(H1N1)pdm09, 410 influenza A(H3), 113 influenza A(not subtyped) and 11 influenza B) with a positivity of 17.9%, which remains above the baseline threshold of 9.7%.

- Sentinel swabbing schemes in England (RCGP) and the Devolved Administrations

In week 49 2019, 66 samples tested positive for influenza (2 influenza A(H1N1)pdm09, 59 influenza A(H3), 4 influenza A(not subtyped) and one co-infection of influenza A(not subtyped) and influenza B), with an overall positivity of 36.6% compared to 38.9% in the previous week, through the UK GP sentinel swabbing schemes (Figure 10).

Since week 40, a total of 328 samples (16 influenza A(H1N1)pdm09, 275 influenza A(H3N2), 21 influenza A(not subtyped), 10 influenza B, one co-infection of influenza A(H3N2) and B, three co-infections of influenza A(H1N1)pdm09 and B, one co-infection of influenza A(H1N1)pdm09 and influenza A(H3) and two co-infections of influenza A(not subtyped) and B) tested positive for influenza through this scheme.

*The Moving Epidemic Method has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity in a standardised approach across Europe. The threshold to indicate a likelihood of influenza community circulation for Datamart % positive as calculated through the Moving Epidemic Method is 9.7% in 2019/20.*
- **Virus characterisation**

PHE characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

The PHE Respiratory Virus Unit has characterised 154 influenza A(H3N2) viruses detected since week 40. Genetic characterisation of 135 of these shows that 111 belong to the genetic clade 3C.3a, and 24 fall into a cluster within the 3C.2a1 subclade, designated 3C.2a1b. The Northern Hemisphere 2019/20 influenza A(H3N2) vaccine strain belongs in genetic subclade 3C.3a. Fifty-four A(H3N2) viruses have been antigenically characterised and are similar to the A/Kansas/14/2017-like Northern Hemisphere 2019/20 (H3N2) vaccine strain. Difficulties remain with detection and typing of A(H3N2) viruses by HI assays due to observed receptor binding changes, particularly with viruses from the 3C.2a1 subclade and these are under-represented in the antigenic characterisation data.

A total of eight A(H1N1)pdm09 viruses have been characterised to date. Six A(H1N1)pdm09 viruses have been genetically characterised, all fall in clade 6B.1A which was the predominant genetic clade in the 2018/19 season. Five A(H1N1)pdm09 viruses have been antigenically characterised and are similar to the A/Brisbane/02/2018-like N. Hemisphere 2019/20 A(H1N1)pdm09 vaccine strain.

One influenza B virus has been characterised to date, where sequencing of the haemagglutinin (HA) gene shows this virus belongs in genetic clade 1A of the B/Victoria lineage, clustering in a subgroup within this clade characterised by deletion of three amino acids in the HA. The N. Hemisphere 2019/20 B/Victoria-lineage quadrivalent and trivalent vaccine component virus (a B/Colorado/06/2017-like virus) belongs in genetic clade 1A, clustering in a subgroup with two deletions in the HA.

At this early stage of the influenza season, it is too early to predict which lineages will dominate throughout the season, a process that can be assisted with the evaluation of vaccine effectiveness.

### Table 3: Viruses characterised by PHE Reference Laboratory, 2019/20

<table>
<thead>
<tr>
<th>Virus type/subtype</th>
<th>Genetic and antigenic</th>
<th>Genetic only</th>
<th>Antigenic only</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>A(H1N1)pdm09</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>A(H3N2) 3C.2a1</td>
<td>0</td>
<td>24</td>
<td>0</td>
<td>24</td>
</tr>
<tr>
<td>A(H3N2) 3C.3a</td>
<td>35</td>
<td>76</td>
<td>19</td>
<td>130</td>
</tr>
<tr>
<td>A(H3N2) total</td>
<td>35</td>
<td>100</td>
<td>19</td>
<td>154</td>
</tr>
<tr>
<td>B/Yamagata-lineage</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>B/Victoria-lineage</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

- **Antiviral susceptibility**

Influenza positive samples are screened for mutations in the virus neuraminidase gene known to confer oseltamivir and/or zanamivir resistance. Additionally, testing of influenza A(H1N1)pdm09, A(H3N2), and influenza B virus isolates for neuraminidase inhibitor susceptibility (oseltamivir and zanamivir) is performed at PHE-RVU using a functional assay. The data summarized below combine the results of both testing methods. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with neuraminidase inhibitor-resistant virus is also performed.

Since week 40 2019, 9 influenza A (H1N1) viruses and 28 influenza A (H3N2) viruses were tested for their susceptibility for both antiviral agents, oseltamivir and zanamivir, and all viruses were sensitive.

- **Antimicrobial susceptibility**

-Table 4 shows in the 12 weeks up to 08 December 2019, the proportion of all lower respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, MRSA and MSSA tested and susceptible to antibiotics. These organisms are the key causes of community-acquired pneumonia (CAP) and the choice of antibiotics reflects the British Thoracic Society empirical guidelines for management of CAP in adults.

### Table 4: Antimicrobial susceptibility surveillance in lower respiratory tract isolates, 12 weeks up to 08 December 2019, E&W

<table>
<thead>
<tr>
<th>Organism</th>
<th>Antibiotic</th>
<th>Specimens tested (N)</th>
<th>Specimens susceptible (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. pneumoniae</td>
<td>Penicillin</td>
<td>3639</td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>3973</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>3924</td>
<td>82</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>Amoxicillin/amoxicillin</td>
<td>1363</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Co-amoxiclav</td>
<td>15061</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>2532</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>15125</td>
<td>86</td>
</tr>
<tr>
<td>S. aureus</td>
<td>Methicillin</td>
<td>6911</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>7715</td>
<td>66</td>
</tr>
<tr>
<td>MRSA</td>
<td>Clindamycin</td>
<td>398</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>589</td>
<td>79</td>
</tr>
<tr>
<td>MSSA</td>
<td>Clindamycin</td>
<td>4581</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>6006</td>
<td>92</td>
</tr>
</tbody>
</table>

*Macrolides = erythromycin, azithromycin and clarithromycin*
• Up to week 49 2019 in 93.2% of GP practices reporting weekly to Immform for the main collection, the provisional proportion of people in England who had received the 2019/20 influenza vaccine in targeted groups was as follows (Figure 14):
  - 37.1% in under 65 years in a clinical risk group
  - 38.8% in pregnant women
  - 68.5% in 65+ year olds

![Figure 14: Cumulative weekly influenza vaccine uptake by target group in England](image)

• In 2019/20, all 2 and 3 year olds continue to be eligible for influenza vaccination through their GPs. Up to week 49 2019, in 92.8% of GP practices reporting weekly to Immform for the childhood collection, the provisional proportion of children in England who had received the 2019/20 influenza vaccine in targeted groups was as follows (Figure 15):
  - 28.9% in 2 year olds
  - 28.1% in 3 year olds

![Figure 15: Cumulative weekly influenza vaccine uptake by target group in England](image)

• Provisional data from the first monthly collection of the influenza vaccine uptake by frontline healthcare workers show 43.6% were vaccinated by 31 October 2019 from 96.6% of all organisations, compared to 46.3% vaccinated in the previous season by 31 October 2018. The report provides uptake at national, NHS England local team and Trust-level.
Provisional data from the first monthly collection of influenza vaccine uptake for children of school years Reception, 1, 2, 3, 4, 5 and 6 age (from a sample of 100% of all Local Authorities in England) show the provisional proportion of children in England who received the 2019/20 influenza vaccine via school, pharmacy or GP practice by 31 October 2019 in targeted groups in Table 5.

### Table 5: Provisional cumulative influenza vaccine uptake (%) in children in school years Reception to Year 6, up to 31 October 2019 & 2018, England

<table>
<thead>
<tr>
<th>School Year</th>
<th>% Vaccine uptake (up to 31 October)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2019/20</td>
</tr>
<tr>
<td></td>
<td>2018/19</td>
</tr>
<tr>
<td>Reception (4-5 years)</td>
<td>17.9</td>
</tr>
<tr>
<td></td>
<td>20.5</td>
</tr>
<tr>
<td>Year 1 (5-6 years)</td>
<td>17.6</td>
</tr>
<tr>
<td></td>
<td>20.7</td>
</tr>
<tr>
<td>Year 2 (6-7 years)</td>
<td>17.3</td>
</tr>
<tr>
<td></td>
<td>19.9</td>
</tr>
<tr>
<td>Year 3 (7-8 years)</td>
<td>16.6</td>
</tr>
<tr>
<td></td>
<td>19.7</td>
</tr>
<tr>
<td>Year 4 (8-9 years)</td>
<td>16.4</td>
</tr>
<tr>
<td></td>
<td>18.9</td>
</tr>
<tr>
<td>Year 5 (9-10 years)</td>
<td>15.8</td>
</tr>
<tr>
<td></td>
<td>18.2</td>
</tr>
<tr>
<td>Year 6 (10-11 years)</td>
<td>15.2</td>
</tr>
<tr>
<td></td>
<td>-</td>
</tr>
</tbody>
</table>

- : Year 6 were not part of the programme in 2018/19

---

### International Situation

In the temperate zone of the northern hemisphere, influenza activity and respiratory illness indicators started to increase in most countries with influenza activity elevated across the countries in Western Asia. In the temperate zones of the southern hemisphere, influenza activity returned to interseasonal levels. Worldwide, seasonal influenza A(H3N2) viruses accounted for the majority of detections.

- **Europe** updated on 06 December 2019 (Joint ECDC-WHO Europe Influenza weekly update)

Overall in week 48, influenza activity continued to increase in parts of the Region, with the majority of countries reporting influenza A virus detections dominance. Influenza virus detections in sentinel specimens exceeded 10% for the second consecutive week, which indicates the start of the influenza season at European level.

For week 48 2019, of 47 Member States and areas reporting on intensity, 41 reported baseline and 5 reported low intensity and 1 reported medium intensity. Of 46 Member States and areas reporting on geographic spread, 12 reported no activity, 22 reported sporadic cases, 9 reported local spread (across the Region), 1 reported regional spread and 2 reported widespread activity.

For week 48/2019, 140 (13.8%) of 1 016 sentinel specimens tested positive for influenza viruses; 71% were type A and 29% were type B. Of 90 subtyped A viruses, 39% were A(H1N1)pdm09 and 61% were A(H3N2). Of 13 type B viruses ascribed to a lineage, 12 were B/Victoria and 1 was B/Yamagata.

For week 48 2019, of 47 Member States and areas reporting on intensity, 41 reported baseline and 5 reported low intensity and 1 reported medium intensity. Of 46 Member States and areas reporting on geographic spread, 12 reported no activity, 22 reported sporadic cases, 9 reported local spread (across the Region), 1 reported regional spread and 2 reported widespread activity.

For week 47 2019, pooled estimates from the EuroMOMO project of all-cause mortality from 21 countries or areas show all-cause mortality were within expected range for the time of year.

- **United States of America** updated on 06 December 2019 (Centre for Disease Control report)

During week 48, influenza activity continues to increase and has been elevated for the past four weeks. Nationwide during week 48, 3.5% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI), which is above the national baseline of 2.4%.
During week 48, 10.2% of respiratory specimens tested by clinical laboratories were influenza positive. This is higher than the previous week.

The overall hospitalisation rate for the season is 2.7 per 100,000. This is similar to what has been seen at this time in recent previous seasons.

Based on National Center for Health Statistics (NCHS) mortality surveillance data available on 05 December 2019, 4.8% of the deaths occurring during the week ending November 23, 2019 (week 47) were due to P&I. This percentage is below the epidemic threshold of 6.4% for week 47.

- **Canada** updated on 06 December 2019 (Public Health Agency report)

At national level, influenza activity continues to increase at the national level in week 48, with influenza A(H3N2) continuing to be the most common influenza virus circulating in Canada.

In weeks 48, a total of 515 laboratory detections of influenza were reported, of which 60% (307) were influenza A, with 58/98 subtyped influenza A detections being influenza A(H3N2).

The percentage of tests positive for influenza was above the seasonal threshold of 5.0%, at 8.0% in week 48.

In week 48, 1.3% of visits to healthcare professionals were due to ILI, respectively.

To date this season, 152 influenza-associated hospitalisations have been reported with the majority of cases being aged greater than 65 years and associated with influenza A(H3N2).

- **Global influenza update** updated on 09 December 2019 (based on data up to 24 November 2019) (WHO website)

In the temperate zone of the northern hemisphere, influenza activity and respiratory illness indicators started to increase in most countries with influenza activity elevated across the countries in Western Asia. In the temperate zones of the southern hemisphere, influenza activity returned to interseasonal levels. Worldwide, seasonal influenza A(H3N2) viruses accounted for the majority of detections.

In the countries of North America, ILI and influenza activity crossed the seasonal baseline, with co-circulation of all seasonal influenza subtypes.

In Europe, influenza activity continued to increase, with influenza A viruses predominant in most countries, and B viruses in several countries of the eastern part of the region.

In Central Asia, some marginal increases in respiratory illness indicators were reported in most countries.

In Northern Africa, activity remained at inter-seasonal levels, except for Morocco where low detections of influenza B/Victoria lineage viruses were reported in recent weeks.

In Western Asia, influenza activity continued to increase overall. In Bahrain, Kuwait and Saudi Arabia, influenza activity continued to increase with detections of predominately influenza A(H1N1)pdm09 and a small proportion of B viruses. Kuwait and Oman continued to report influenza detections at lower levels compared to previous weeks. In Qatar, influenza A(H3N2) viruses were most frequently detected. Increased SARI levels continued to be reported in Saudi Arabia.

In East Asia, ILI and influenza activity increased slightly in most countries, but remained low overall. ILI activity was reported above the seasonal threshold in the Republic of Korea, with detections of predominately influenza A(H1N1)pdm09.

In the Caribbean countries and the tropical countries of South America, influenza activity was low in general.

In Western Africa, influenza activity was elevated in some reporting countries. Increased influenza virus detections with predominantly influenza A(H3N2) and B/Victoria lineage viruses continued to be reported in Ghana, and Guinea and decreased detections were reported in Mali.

In Middle Africa, Cameroon reported increased influenza activity with detections of all seasonal influenza subtypes. South Sudan reported low detections of influenza B/Victoria lineage viruses.
In Eastern Africa, influenza detections were low across most reporting countries. Increased SARI activity and influenza A and B detections were reported in Kenya. Increased ILI activity was reported in Zambia with no detections of influenza viruses.

In Southern Asia, influenza detections were low across reporting countries except for Iran (Islamic Republic of) where influenza activity continued to increase with detections of predominantly influenza A(H1N1)pdm09 viruses. In South East Asia, influenza activity was reported in some countries

The WHO GISRS laboratories tested more than 92,883 specimens between 11 November 2019 and 24 November 2019. 7,914 were positive for influenza viruses, of which 5,629 (71.1%) were typed as influenza A and 2,285 (28.9%) as influenza B. Of the sub-typed influenza A viruses, 1,069 (28.5%) were influenza A (H1N1)pdm09 and 2,682 (71.5%) were influenza A (H3N2). Of the characterized B viruses, 34 (3.2%) belonged to the B-Yamagata lineage and 1,014 (96.8%) to the B-Victoria lineage.

- **Avian Influenza** latest update on 27 September 2019 (WHO website)

**Influenza A(H5) viruses**

Between 25 June 2019 to 27 September 2019, one new laboratory-confirmed human case of influenza A(H5N6) virus infection was reported to WHO.

A total of 24 laboratory-confirmed cases of human infection with influenza A(H5N6) virus have been reported to WHO from China since 2014.

According to reports received by the World Organization for Animal Health (OIE), various influenza A(H5) subtypes continue to be detected in birds in Africa, Europe and Asia.

**Influenza A(H7N9)**

Between 25 June 2019 and 27 September 2019, no new laboratory-confirmed human case of influenza A(H7N9) virus infection were reported to WHO from China. Publicly available reports from animal health authorities in China of influenza A(H7N9) virus detections in animals in recent months indicate virus detections in two provinces from samples taken in the first half of the year. 5 Overall, the risk assessment has not changed.

For more information on A(H5), A(H7N9), A(H9N2) and A(H1)v viruses, please see the September 2019 report: **Antigenic and genetic characteristics of zoonotic influenza viruses and candidate vaccine viruses developed for potential use in human vaccines.**

- **Middle East respiratory syndrome coronavirus (MERS-CoV)** latest update on 11 December 2019

Up to 11 December 2019, a total of five cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (three imported and two linked cases) have been confirmed in the UK. On-going surveillance has identified 1,719 suspected cases in the UK since September 2012 that have been investigated for MERS-CoV and tested negative.

Between 1 and 31 October 2019, the National IHR Focal Point of Saudi Arabia reported 15 additional cases of Middle East respiratory syndrome (MERS-CoV) infection and six associated deaths.

On 7 October 2019, the National IHR Focal Point of the United Arab Emirates (UAE) notified WHO of one laboratory-confirmed case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.

Globally, since September 2012 and up to 31 October 2019, WHO has been notified of 2,484 laboratory-confirmed cases of infection with MERS-CoV, including 857 related deaths. Further information on management and guidance of possible cases is available online. The latest ECDC MERS-CoV risk assessment can be found [here](https://www.ecdc.europa.eu/en), where it is highlighted that risk of widespread transmission of MERS-CoV remains very low.

**Acknowledgements**

This report was prepared by the Influenza Surveillance Section, Immunisations and Countermeasures Division, National Infection Service, Public Health England. We are grateful to all who provided data for this report including the RCGP Research and Surveillance Centre, the PHE Real-time Syndemic Surveillance team, the PHE Respiratory Virus Unit, the PHE Modelling and Statistics unit, the PHE Dept. of Healthcare Associated Infection &
Antimicrobial Resistance, PHE regional microbiology laboratories, Office for National Statistics, the Department of Health, Health Protection Scotland, National Public Health Service (Wales), the Public Health Agency Northern Ireland, the Northern Ireland Statistics and Research Agency, QSurveillance® and EMIS and EMIS practices contributing to the QSurveillance® database.

Related links

Sources of flu data
- Clinical surveillance through primary care in the UK
- Outbreak reporting
- FluSurvey
- MQSA
- Real time syndromic surveillance
- MEM threshold methodology paper and UK pilot paper

Disease severity and mortality data
- USISS system
- EuroMOMO mortality project

Vaccination
- Seasonal influenza vaccine programme (Department of Health Book)
- Childhood flu programme information for healthcare practitioners (Public Health England)
- 2019/20 Northern Hemisphere seasonal influenza vaccine recommendations (WHO)